In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BGI Touts Eventual Merck Deal

Executive Summary

Beijing Genomics and Merck intend to collaborate, using BGI resources primarily to analyze genomic and epigenetic data off of Merck samples. The announcement was more than just a shot across the bow signaling BGI's intent to dominate the gene sequencing services world. It could eventually extend into the clinical arena, which could open up another whole new collaborative - and competitive - area with the West.
Advertisement

Related Content

Regeneron And Geisinger Get Ambitious In Next-Gen Genomics
Personalized Medicine In 2010: Welcome To The Establishment
The How And When Of Applying Sequencing To Clinical Diagnostics
The How And When Of Applying Sequencing To Clinical Diagnostics
Lilly and Merck Lead the Way With Asian FIPNet Strategies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel